Gail Farfel
Director/Board Member at DURECT CORPORATION
Net worth: 118 764 $ as of 2024-05-30
Gail Farfel active positions
| Companies | Position | Start | End |
|---|---|---|---|
| DURECT CORPORATION | Director/Board Member | 2019-04-24 | - |
| Independent Dir/Board Member | 2019-04-24 | - | |
| AVROBIO, INC. | Director/Board Member | 2020-10-20 | - |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Director/Board Member | - | - |
| American Society For Experimental Neurotherapeutics | Director/Board Member | - | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Director/Board Member | 2014-08-06 | - |
Career history of Gail Farfel
Former positions of Gail Farfel
| Companies | Position | Start | End |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Director/Board Member | 2023-06-28 | 2023-12-29 |
| Chief Executive Officer | 2022-09-18 | 2023-12-29 | |
| President | 2022-09-18 | 2023-12-29 | |
| ZOGENIX, INC. | Corporate Officer/Principal | 2015-05-31 | 2022-08-31 |
| MARINUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2012-11-30 | 2015-05-31 |
| General Counsel | 2012-11-30 | 2015-05-31 | |
| G Meredith Consulting LLC | President | 2008-04-30 | 2012-11-30 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Gail Farfel
| University of Virginia | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Statistics
International
| United States | 13 |
| Canada | 3 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 7 |
| Corporate Officer/Principal | 4 |
| President | 2 |
Sectoral
| Health Technology | 11 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
| G Meredith Consulting LLC | |
| American Society For Experimental Neurotherapeutics |
- Stock Market
- Insiders
- Gail Farfel
- Experience
